产品
编 号：F284986
分子式：C29H26ClFN4O4S
分子量：581.06
分子式：C29H26ClFN4O4S
分子量：581.06
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
50mg
560
In-stock
100mg
960
In-stock
500mg
2400
In-stock
1g
3600
In-stock
结构图
CAS No: 231277-92-2
产品详情
生物活性：
Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
体内研究：
Lapatinib (GW2016; 30-100 mg/kg; oral administration; twice daily; for 21 days; CD-1 nude female mice) treatment inhibits tumor xenograft growth of the HN5 cells in a dose-responsive manner at 30 and 100 mg/kg, with complete inhibition of tumor growth at the higher dose.Animal Model:CD-1 nude female mice (4-6 weeks old) with HN5 cells
Dosage:30 mg/kg, 100 mg/kg
Administration:Oral administration; twice daily; for 21 days
Result:Inhibited tumor xenograft growth of the HN5 cells in a dose-responsive manner.
体外研究：
Lapatinib (GW2016; 0.03-10 μM; 6 hours; BT474 and HN5 cells) treatment inhibits receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was inhibited by GW2016 in a dose-dependent manner.Lapatinib (GW2016; 72 hours; HN5, A-43, BT474, N87, and CaLu-3 cells) treatment has a selective inhibition of the proliferation of human tumor cell lines.Lapatinib (GW2016; 1-10 μM; 72 hours; HN5 cells) treatment results in induces G1 arrest.
Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
体内研究：
Lapatinib (GW2016; 30-100 mg/kg; oral administration; twice daily; for 21 days; CD-1 nude female mice) treatment inhibits tumor xenograft growth of the HN5 cells in a dose-responsive manner at 30 and 100 mg/kg, with complete inhibition of tumor growth at the higher dose.Animal Model:CD-1 nude female mice (4-6 weeks old) with HN5 cells
Dosage:30 mg/kg, 100 mg/kg
Administration:Oral administration; twice daily; for 21 days
Result:Inhibited tumor xenograft growth of the HN5 cells in a dose-responsive manner.
体外研究：
Lapatinib (GW2016; 0.03-10 μM; 6 hours; BT474 and HN5 cells) treatment inhibits receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was inhibited by GW2016 in a dose-dependent manner.Lapatinib (GW2016; 72 hours; HN5, A-43, BT474, N87, and CaLu-3 cells) treatment has a selective inhibition of the proliferation of human tumor cell lines.Lapatinib (GW2016; 1-10 μM; 72 hours; HN5 cells) treatment results in induces G1 arrest.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备